Core Viewpoint - Rongchang Biologics (09995) experienced a significant stock increase, rising over 7% in the afternoon trading session, with a current price of 90.75 HKD and a trading volume of 319 million HKD, driven by positive clinical research news regarding its product candidates [1] Group 1: Clinical Research Developments - At the 2025 ESMO annual meeting, the clinical study results for Vidisicimab combined with Toripalimab versus chemotherapy for first-line treatment of HER2-expressing locally advanced or metastatic urothelial carcinoma were released, indicating a major shift in the treatment landscape for urothelial carcinoma [1] - Yongxing Securities reported that the combination therapy of Vidisicimab shows excellent immunotherapy efficacy, marking a significant change in the treatment paradigm for urothelial carcinoma [1] Group 2: Product Pipeline and Market Potential - CITIC Construction Investment (601066) highlighted that in 2025, the core product Taitasip will rapidly expand after receiving approval for new indications, and the data for the combination treatment of Vidisicimab is promising [1] - The application for the market approval of RC28 for DME indication has been accepted, and the investigational pipeline includes RC148, which has received breakthrough therapy designation, with continuous validation of its clinical data [1] - Overall, the company is accelerating its commercialization process and has a well-structured pipeline, indicating a positive outlook for future development [1]

Core Viewpoint - Recent stock transfer of Rongchang Biologics (09995) from BNP Paribas to HSBC Hong Kong valued at HKD 896 million, representing 5.29% of the company [1] Group 1: Stock Transfer - On November 26, shareholders of Rongchang Biologics transferred shares from BNP Paribas to HSBC Hong Kong, with a market value of HKD 896 million [1] Group 2: Analyst Report - Jianyin International raised the target price for Rongchang Biologics by 9% from HKD 110 to HKD 120, maintaining an "outperform" investment rating [1] - The revenue forecasts for Rongchang Biologics for 2025, 2026, and 2027 remain unchanged at RMB 2.8 billion, RMB 3.4 billion, and RMB 4.6 billion respectively [1]

Group 1 - The Hong Kong pharmaceutical and biotechnology sector showed strong performance on November 26, with notable gains in several companies [1] - Rongchang Biopharmaceutical, CSPC Pharmaceutical Group, and 3SBio each saw their stock prices increase by over 6% [1] - Other companies such as Fuhong Hanlin, Cornerstone Pharmaceuticals, and China National Pharmaceutical Group also experienced significant price increases [1]

Core Viewpoint - The company, Rongchang Biopharmaceutical (Yantai) Co., Ltd., is set to hold a third-quarter earnings presentation on December 3, 2025, to discuss its operational results and financial status for Q3 2025, allowing investors to engage in a Q&A session [2][3][4]. Group 1: Meeting Details - The earnings presentation will take place on December 3, 2025, from 13:00 to 14:00 [2][4]. - The venue for the meeting is the Shanghai Stock Exchange Roadshow Center, and it will be conducted in an interactive online format [2][4][5]. - Investors can submit questions from November 26, 2025, to December 2, 2025, before 16:00, either through the Roadshow Center website or via the company's email [2][5]. Group 2: Company Representatives - Key representatives attending the meeting include the Chairman, Mr. Wang Weidong, and the General Manager, Mr. Fang Jianmin [4]. - The meeting will also feature the company’s Board Secretary, Mr. Wen Qingkai, and the Chief Financial Officer, Mr. Tong Shaojing [4]. Group 3: Investor Participation - Investors can participate in the earnings presentation by logging into the Shanghai Stock Exchange Roadshow Center [5]. - After the meeting, the main content and proceedings will be available for review on the Roadshow Center's website [5].

荣昌生物制药（烟台）股份有限公司 股东会会议资料 荣昌生物制药（烟台）股份有限公司 2025 年第三次临时股东会 会议资料 股票简称：荣昌生物 股票代码：688331 2025 年 12 月 荣昌生物制药（烟台）股份有限公司 股东会会议资料 荣昌生物制药（烟台）股份有限公司 会议资料目录 三、会议议案 2 一、会议须知 二、会议议程 1、议案一：《关于预计 2026-2028 年度日常关联交易的议案》 2、议案二：《关于修订公司部分治理制度的议案》 荣昌生物制药（烟台）股份有限公司 股东会会议资料 1 荣昌生物制药（烟台）股份有限公司 2025 年第三次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证 会议的顺利进行，根据《中华人民共和国公司法》（以下简称"《公司 法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、中国证监 会《上市公司股东会规则》以及《荣昌生物制药（烟台）股份有限公司章程》、 《荣昌生物制药（烟台）股份有限公司股东会议事规则》的相关规定，特制定 本会议须知： 一、为确认出席会议的股东或其代理人或其他出席者的出席资格，会议工 作人员将对出席会议者 ...

| 证券代码：688331 | 证券简称：荣昌生物 | 公告编号：2025-052 | | --- | --- | --- | | 港股代码：09995 | 港股简称：榮昌生物 | | 荣昌生物制药（烟台）股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 12 月 03 日 （星期三） 13:00-14:00 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 26 日（星期三）至 12 月 02 日（星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@remegen.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 荣昌生物制药(烟台)股份有限公司（以下简称"公司"）已于 2025 年 10 月 31 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 12 ...

Core Viewpoint - Jianyin International has raised the target price for Rongchang Biologics (09995) by 9% from HKD 110 to HKD 120, maintaining an "outperform" investment rating [1] Revenue Forecast - Jianyin International has kept its revenue forecasts for Rongchang Biologics for 2025, 2026, and 2027 unchanged at RMB 2.8 billion, RMB 3.4 billion, and RMB 4.6 billion respectively [1] Loss Adjustments - Due to improved operational efficiency, the ratio of operating expenses to sales has decreased, leading to a downward adjustment of the 2025 adjusted net loss forecast from RMB 347 million to RMB 68 million [1] - The 2026 adjusted net loss forecast has also been revised down from RMB 182 million to RMB 94 million [1] Profit Forecast - The adjusted profit forecast for 2027 has been increased from RMB 923 million to RMB 960 million [1]

Core Viewpoint - Jianyin International has raised the target price for Rongchang Biopharmaceutical (09995) by 9% from HKD 110 to HKD 120, maintaining an "outperform" investment rating [1] Revenue Forecast - Jianyin International has kept its revenue forecasts for Rongchang Biopharmaceutical for 2025, 2026, and 2027 unchanged at RMB 2.8 billion, RMB 3.4 billion, and RMB 4.6 billion respectively [1] Loss Adjustment - Due to improved operational efficiency, the ratio of operating expenses to sales has decreased, leading to a downward adjustment of the 2025 adjusted net loss forecast from RMB 347 million to RMB 68 million [1] - The 2026 adjusted net loss forecast has also been revised down from RMB 182 million to RMB 94 million [1] Profit Forecast - The adjusted profit forecast for 2027 has been increased from RMB 923 million to RMB 960 million [1]

Core Viewpoint - Rongchang Biopharmaceuticals has experienced significant stock price fluctuations and changes in shareholder composition, reflecting its ongoing developments in the biopharmaceutical sector and market dynamics [1][3][4]. Group 1: Stock Performance - As of November 17, Rongchang Biopharmaceuticals' stock price decreased by 2.01%, trading at 88.27 CNY per share, with a market capitalization of 49.759 billion CNY [1]. - The stock has increased by 193.16% year-to-date, with a slight increase of 0.02% over the last five trading days, a decrease of 6.59% over the last 20 days, and an increase of 14.65% over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" four times this year, with the most recent instance on June 26, where it recorded a net buy of -137 million CNY [1]. Group 2: Company Overview - Rongchang Biopharmaceuticals, established on July 4, 2008, and listed on March 31, 2022, is based in Yantai, Shandong, China, focusing on innovative biopharmaceuticals, particularly in antibody-drug conjugates (ADC) and therapeutic antibodies [2]. - The company aims to develop first-in-class and best-in-class biopharmaceuticals to address unmet clinical needs in autoimmune diseases, oncology, and ophthalmology [2]. - The revenue composition shows that 99.46% comes from product sales, with minimal contributions from material sales and leasing services [2]. Group 3: Financial Performance - For the period from January to September 2025, Rongchang Biopharmaceuticals reported a revenue of 1.72 billion CNY, representing a year-on-year growth of 42.27%, while the net profit attributable to shareholders was -551 million CNY, an increase of 48.60% year-on-year [3]. Group 4: Shareholder Composition - As of September 30, 2025, the number of shareholders increased by 18.33% to 15,300, with an average of 10,639 circulating shares per shareholder, a decrease of 15.54% [3]. - The second-largest shareholder is Hong Kong Central Clearing Limited, holding 8.8418 million shares, a decrease of 510,800 shares from the previous period [4]. - Other notable shareholders include Wanjiayou Selected (increased by 1.0755 million shares) and new entrant Guangfa Healthcare Stock A [4].

Core Viewpoint - Rongchang Biopharmaceuticals has experienced significant stock price fluctuations and is focusing on innovative biopharmaceuticals, particularly in the field of therapeutic antibodies [1][2][3]. Financial Performance - As of September 30, 2025, Rongchang Biopharmaceuticals reported a revenue of 1.72 billion yuan, representing a year-on-year growth of 42.27% [3]. - The company recorded a net profit attributable to shareholders of -551 million yuan, which is a 48.60% increase compared to the previous period [3]. Stock Market Activity - On November 14, 2025, the stock price of Rongchang Biopharmaceuticals fell by 2.04%, trading at 87.18 yuan per share with a market capitalization of 49.135 billion yuan [1]. - The stock has increased by 189.54% year-to-date, with a recent 5-day increase of 0.28% and a 20-day decline of 10.47% [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders increased by 18.33% to 15,300, while the average circulating shares per person decreased by 15.54% to 10,639 shares [3][4]. - Major shareholders include Hong Kong Central Clearing Limited and Wanjiayouxuan, with notable changes in their holdings [4].